(Q35674616)

English

A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).

scientific article published on 25 June 2015

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Gunter von Minckwitz

1

object named as

Gunter von Minckwitz

0 references

Wolfgang Eiermann

6

object named as

Wolfgang Eiermann

0 references

20

object named as

Sibylle Loibl

0 references

Holger Eidtmann

5

object named as

Holger Eidtmann

0 references

Valentina Nekljudova

18

object named as

Valentina Nekljudova

0 references

14

object named as

Jens Huober

0 references

Frederik Marmé

9

object named as

Frederik Marmé

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

author name string

Bettina Conrad

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Toralf Reimer

3

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Thomas Decker

4

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

John Hackmann

7

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Volker Möbus

8

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Jochem Potenberg

10

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Elmar Stickeler

11

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Eike Simon

12

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Christoph Thomssen

13

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Carsten Denkert

15

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Joachim Alfer

16

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Christian Jackisch

17

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Nicole Burchardi

19

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

German Breast Group Investigators

21

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

0 references

publication date

25 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

121

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

3639-3648

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29506

21 January 2018

Undertreatment strongly decreases prognosis of breast cancer in elderly women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29506

21 January 2018

Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29506

21 January 2018

Adjuvant chemotherapy in older women with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29506

21 January 2018

Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29506

21 January 2018

First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29506

21 January 2018

Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29506

21 January 2018

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29506

21 January 2018

A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29506

21 January 2018

Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29506

21 January 2018

Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29506

21 January 2018

Survival of women after breast conserving surgery for early stage breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29506

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29506

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.29506

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35674616&oldid=1570012981"